Company Encyclopedia
View More
name
Haisco
002653.SZ
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. The company offers pharmaceutical products in the areas of anesthesia and analgesia, diabetes mellitus and complications, tumor, neuralgia, parenteral nutrition, cardio-cerebrovascular, digestive and respiratory, narcotic analgesics, endocrine system, enteral parenteral, nutrition, neuropsychiatric, cardiovascular, digestive liver, and other diseases. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd.
3.157 T
002653.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking6/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.34%B
    • Profit Margin7.23%B
    • Gross Margin75.37%A
  • Growth ScoreB
    • Revenue YoY14.72%B
    • Net Profit YoY-35.12%D
    • Total Assets YoY4.39%C
    • Net Assets YoY1.05%C
  • Cash ScoreB
    • Cash Flow Margin1382.24%B
    • OCF YoY14.72%B
  • Operating ScoreB
    • Turnover0.6B
  • Debt ScoreC
    • Gearing Ratio41.43%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial

    Haisco Pharma Gets Nod for Myasthenia Gravis Drug Trial

    marketscreener·
    SZ
    002653
    -0.38%
    marketscreener·
    SZ
    002653
    -0.38%

    Haisco: Clinical trial for new indication drug HSK39297 approved

    According to the Zhitong Finance APP, Haisco announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration's Review Center. The drug name is HSK39297 tablets, and its indication is for generalized myasthenia gravis

    Zhitong·
    SZ
    002653
    -0.38%
    Zhitong·
    SZ
    002653
    -0.38%

    Guojin Securities: The differentiation in the pharmaceutical industry track continues in Q3 2025, with accelerated release of innovative drugs

    Guojin Securities released a research report indicating that the overall performance of the pharmaceutical industry will be stable in the third quarter of 2025, with profits showing some improvement. Pharma companies are exhibiting differentiated performances, with large enterprises making faster progress in innovation and transformation performing better. Biotech companies are rapidly increasing their volume, approaching breakeven. From the first to the third quarter of 2025, the overall revenue and net profit attributable to the parent company in the pharmaceutical sector are expected to grow at rates of -3% and -8%, respectively, while the growth rates for the third quarter of 2025 are projected to be -1% and +17%

    Zhitong·
    SZ
    002653
    -0.38%
    SZ
    002422
    -1.09%
    Zhitong·
    SZ
    002653
    -0.38%
    SZ
    002422
    -1.09%

    On the morning of the first session of the 2025 National Negotiation, 6 pharmaceutical companies have completed negotiations and exited, involving products including analgesics and anti-infectives

    The national medical insurance catalog on-site negotiations for 2025 were held on October 30, with 6 pharmaceutical companies completing the negotiations and leaving, involving analgesics and anti-infection drugs. Participating companies include Haisco, Yifan Pharmaceutical, Astrazeneca, CSPC PHARMA, and LUYE PHARMA. Astrazeneca Vice President Huang Bin left the negotiations with a smile

    Zhitong·
    US
    AZN
    -0.90%
    HK
    01093
    +0.78%
    HK
    02186
    -0.99%
    Zhitong·
    US
    AZN
    -0.90%
    HK
    01093
    +0.78%
    HK
    02186
    -0.99%

    Haisco Pharmaceutical's Q3 Profit Down 23%, Revenue Up 22%

    Haisco Pharmaceutical's Q3 Profit Down 23%, Revenue Up 22%

    marketscreener·
    SZ
    002653
    -0.38%
    marketscreener·
    SZ
    002653
    -0.38%
    © 2025 Longbridge｜Disclaimer